Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

Michael J. Morris, MD
Published: Thursday, Dec 01, 2016


Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).  
 
Radium-223 is a first-in-class radiopharmaceutical; there is really nothing else like it, says Morris.
 
Its mechanism of action results in a very low toxicity profile, says Morris. It has very low homological toxicities, and it prolongs life and delays skeletal-related events. It has a lot of potential to be combined with other agents, says Morris.
 
It is being combined in clinical trials right now with AR-directed therapies. Early studies are also moving forward combining radium-223 with chemotherapy. It cannot be combined with chemotherapy currently, but safety data is forthcoming, says Morris.
 
It is also being investigated in combination with tumor-directed therapy.
 

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).  
 
Radium-223 is a first-in-class radiopharmaceutical; there is really nothing else like it, says Morris.
 
Its mechanism of action results in a very low toxicity profile, says Morris. It has very low homological toxicities, and it prolongs life and delays skeletal-related events. It has a lot of potential to be combined with other agents, says Morris.
 
It is being combined in clinical trials right now with AR-directed therapies. Early studies are also moving forward combining radium-223 with chemotherapy. It cannot be combined with chemotherapy currently, but safety data is forthcoming, says Morris.
 
It is also being investigated in combination with tumor-directed therapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x